Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Sangamo Therapeutics, Inc. (NASDAQ: SGMO).

Full DD Report for SGMO

You must become a subscriber to view this report.


Recent News from (NASDAQ: SGMO)

In-Depth Analysis Of SB-913 Early Clinical Readout For MPS II
Sangamo ( SGMO ) released highly anticipated clinical data of SB-913 using ZFN gene-editing technology ( Press release ) for MPS II on Sep 5, 2018. It attracts huge attention in the gene-editing field as the first in vivo gene-editing therapy trial in the US. The mixed early clinical results p...
Source: SeekingAlpha
Date: September, 11 2018 05:59
Sangamo (Part V): Assessing The Prospects Of SB-913
Cicero learned man that he was, believed in self-improvement so long as his breath lasts. He commends Socrates for learning to play the fiddle late in life and another Roman for mastering Greek when old. - Charlie Munger We are now living in the era of gene therapy. Luxturna (a gene therap...
Source: SeekingAlpha
Date: September, 11 2018 04:14
Sangamo: It Worked, Didn't It?
Sangamo ( SGMO ) presented preliminary results from their first genome editing trial SB-913 . The stock market reaction to these data amounted to a complete reversal of the rally leading up to the presentation. The early results clearly show the desired reduction in glycosaminoglycans or GA...
Source: SeekingAlpha
Date: September, 10 2018 17:57
Sangamo: Did It Work?
Introduction: Twitter's darling Sangamo ( SGMO ) dropped data yesterday from their first-in-human gene editing trial of SB-913. SGMO rode a wave of expectations on their way to the readout, with shares trading up 35% in the previous month. The stock has since plummeted to below previous trad...
Source: SeekingAlpha
Date: September, 07 2018 17:59
Sangamo Tumbles On MPS II Data, But It Was Grossly Misunderstood
Recently, Sangamo Therapeutics ( SGMO ) announced results for its Phase 1/2 study treating patients with a rare disease known as MPS II. I believe that the selloff was irrational because investors weren't focused on the main issue at hand. Instead, they only focused on one negative piece of ...
Source: SeekingAlpha
Date: September, 07 2018 11:02

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1411.4911.4311.7711.332625,065
2018-12-1312.3611.66512.4011.54868,827
2018-12-1211.9012.3512.4511.75868,919
2018-12-1111.9511.7411.9511.56901,886
2018-12-1011.2611.6511.8511.15887,837

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14100,450185,71854.0874Short
2018-12-13131,570205,89963.9003Short
2018-12-1281,378258,11731.5276Cover
2018-12-1195,931211,86345.2797Short
2018-12-1086,656235,06736.8644Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SGMO.


About Sangamo Therapeutics, Inc. (NASDAQ: SGMO)

Logo for Sangamo Therapeutics, Inc. (NASDAQ: SGMO)

Not available

 

Contact Information

 

 

Current Management

  • Edward O. Lanphier II / President, CEO

Current Share Structure

  • Market Cap: $1,618,838,966 - 05/18/2018
  • Issue and Outstanding: 101,494,606 - 05/01/2018

 


Recent Filings from (NASDAQ: SGMO)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 28 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: June, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 15 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: June, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018

 

 


Daily Technical Chart for (NASDAQ: SGMO)

Daily Technical Chart for (NASDAQ: SGMO)


Stay tuned for daily updates and more on (NASDAQ: SGMO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: SGMO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SGMO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SGMO and does not buy, sell, or trade any shares of SGMO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/